Patient P-02632
Therapy response
Unstable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
16%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S12
- Day 38 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 38.
Primary contributors, last 14 days
- Treatment adherence+6
- Toxicity-3
- GI instability+2
- Inflammatory activity+2
- Nutritional resilience-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable86 min
stable · -0.9 vs previous 14 d
Sleep duration
Wearable7.5 h
stable · -0.0 vs previous 14 d
Energy level
Daily log6.1/10
worsening · -0.3 vs previous 14 d
Steps
Wearable9,300
stable · -168 vs previous 14 d
GI burden
Companion15.4/100
worsening · +4.3 vs previous 14 d
Adherence
Companion88.7 %
stable · -1.0 vs previous 14 d
Sleep quality
Wearable64.3/100
stable · -1.9 vs previous 14 d
Glucose, CGM daily mean
CGM134 mg/dL
worsening · +5.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 67 from the failing basin, 63 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4 next day on high-intake days · n 24
Would not help
- BR-03 Behavioural Recommendationonly 30% improved among 10 similar
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4supporter · 95%
- Simple carbohydrates+1.6no signal · 36%
- Insoluble fibre-0.6no signal · 15%
- Caffeine-0.6no signal · 15%
- Dietary fat load-0.5no signal · 16%
- Alcohol+0.5no signal · 15%
- Ultra-processed food-0.2no signal · 15%
- Histamine load0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↓25
- WearableResting HR 75 bpm
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.6 · butyrate capacity 46/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 7.2 h
- Steps
- 8,283
- Resting HR
- 74 bpm
Daily log: GI score 15, nutritional resilience 65, adherence 89.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02552 | 36% | S07 | AD-05 | no change | 29 |
| P-02093 | 33% | S05 | AD-05 | no change | 40 |
| P-02285 | 32% | S14 | AD-05 | no change | 39 |
| P-02031 | 30% | S12 | AD-05 | improved | 47 |
| P-02564 | 37% | S15 | BR-03 | improved | 32 |
| P-02308 | 36% | S13 | BR-03 | no change | 27 |
| P-02522 | 35% | S01 | BR-03 | no change | 40 |
| P-02331 | 34% | S14 | BR-03 | improved | 34 |
| P-02325 | 33% | S19 | BR-03 | no change | 33 |
| P-02087 | 31% | S01 | BR-03 | no change | 40 |
| P-02439 | 31% | S08 | BR-03 | no change | 40 |
| P-02267 | 27% | S09 | BR-03 | no change | 45 |